Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine

Pre-clinicalCompleted
0 watching 0 views this week๐Ÿ’ค Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Nov 3, 2021 โ†’ Jul 20, 2023

About Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine

Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine is a pre-clinical stage product being developed by Pfizer for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT05052307. Target conditions include Covid19.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT05052307Pre-clinicalCompleted